FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.
| PDUFA Date | Drug | Indication | Type | PoA |
|---|---|---|---|---|
| 2026-12-22 | — | hypertension in combination with other antihypertensive drug | NDA | 87% |
PoA = estimated probability of approval from published base rates and live data. See the full PDUFA calendar →
A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for MLYS and 2 more tickers of your choice.
Create Free Account →